Review
Pharmacology & Pharmacy
Olga Mulas, Giovanni Caocci, Brunella Mola, Giorgio La Nasa
Summary: This study found that hypertension is a common cardiovascular complication in CML patients treated with second- or third-generation TKI. Compared to the first-generation imatinib, nilotinib and ponatinib were both associated with a significantly increased risk of hypertension.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Oncology
Rafiye Ciftciler, Mehmet G. Akin, Zeynep Erat, A. Emre Eskazan
Summary: The introduction of the first tyrosine kinase inhibitor (TKI), imatinib, has significantly improved the prognosis and life expectancy of chronic myeloid leukemia (CML) patients. Treatment-free remission (TFR), or maintaining a major molecular response without TKI, has been achieved in some CML patients. This systematic review aims to evaluate the characteristics, predictive factors, monitoring, consequences, and studies related to a second TFR (TFR2) after the failure of the first TFR (TFR1). The results indicate that a failed TKI discontinuation attempt in TFR1 does not necessarily lead to a failure in TFR2, and a second discontinuation of TKI can be safe and successful in chronic phase CML patients.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Article
Oncology
Michael Daskalakis, Anita Feller, Jasmine Noetzli, Nicolas Bonadies, Volker Arndt, Gabriela Maria Baerlocher
Summary: The study in Switzerland showed an increase in relative survival for all age groups of CML patients over the decades, with older patients showing a higher increase in survival rates. However, the five-year relative survival rate for the elderly population only reached 53% in the last study period, indicating room for improvement in CML therapy, especially for older patients.
Article
Oncology
Takaaki Ono, Naoto Takahashi, Masahiro Kizaki, Tatsuya Kawaguchi, Ritsuro Suzuki, Kazuhito Yamamoto, Kazunori Ohnishi, Tomoki Naoe, Itaru Matsumura
Summary: Age and comorbidities should be taken into consideration when selecting TKIs for first-line treatment in CML-CP patients. This study found that the choice between imatinib and second-generation TKIs did not significantly impact treatment outcomes, regardless of age. However, older patients had lower overall survival rates compared to younger patients.
Review
Oncology
Hatice Bolek, Yuksel Urun
Summary: The introduction of TKIs and ICIs has greatly transformed the treatment of advanced RCC, though their efficacy after surgical resection remains controversial. Existing risk stratification methods and biomarkers are not accurate enough. This review provides a comprehensive analysis of key phase 3 RCTs, focusing on the use of TKIs, mTOR inhibitors, and ICIs for adjuvant RCC treatment.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2023)
Review
Oncology
Julien Mazieres, Helene Vioix, Boris M. Pfeiffer, Rhiannon I. Campden, Zhiyuan Chen, Bart Heeg, Alexis B. Cortot
Summary: METex14 skipping is a rare oncogenic driver in non-small-cell lung cancer and targeted therapy with MET tyrosine kinase inhibitors has been approved for its treatment. A systematic literature review found that the median frequency of METex14 skipping was 2.0% in unselected NSCLC patients and 2.4% in adenocarcinoma or nonsquamous subgroups. MET TKIs appeared to have higher efficacy outcomes for METex14 skipping NSCLC patients, but direct comparisons with chemotherapy or immunotherapy regimens were lacking.
CLINICAL LUNG CANCER
(2023)
Article
Toxicology
Weiyi Ye, Zhen Wang, Xin Lv, Hang Yin, Lili Jiang, Zhe Wang, Yong Liu
Summary: Ponatinib exhibited potent inhibition against UGTs, especially UGT1A7, UGT1A1, and UGT1A9, which may lead to clinically significant drug-drug interactions.
TOXICOLOGY IN VITRO
(2023)
Review
Oncology
Sarah Nocco, Tyler M. Andriano, Arpita Bose, Marina Chilov, Kendra Godwin, George Dranitsaris, Shenhong Wu, Mario E. Lacouture, Lindsay E. Roeker, Anthony R. Mato, Alina Markova
Summary: This study systematically reviewed the incidence and severity of dermatologic toxicities associated with ibrutinib therapy. The analysis revealed that ibrutinib is associated with various dermatologic adverse events, emphasizing the importance for clinicians to be familiar with them for proper management and improved patient outcomes.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2022)
Review
Oncology
Po-Chun Hsieh, Yao-Kuang Wu, Chun-Yao Huang, Mei-Chen Yang, Chan-Yen Kuo, I-Shiang Tzeng, Chou-Chin Lan
Summary: A meta-analysis was conducted to evaluate the T790M mutation rate after EGFR-TKI treatment, showing that erlotinib and gefitinib had higher rates of T790M mutation compared to afatinib. The T790M mutation rate was significantly lower with afatinib than with gefitinib and erlotinib treatments. T790M mutation plays an important role in determining further treatment and prognosis.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Zhichao Tian, Xiaohui Niu, Weitao Yao
Summary: Apatinib, a multitarget tyrosine kinase inhibitor marketed in China, has shown effectiveness in treating various malignancies such as GC, HCC, lung cancer, breast cancer, and more. This review provides valuable insights for the application and design of clinical trials involving apatinib.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Anna P. Hnatiuk, Arne A. N. Bruyneel, Dhanir Tailor, Mallesh Pandrala, Arpit Dheeraj, Wenqi Li, Ricardo Serrano, Dries A. M. Feyen, Michelle M. Vu, Prashila Amatya, Saloni Gupta, Yusuke Nakauchi, Isabel Morgado, Volker Wiebking, Ronglih Liao, Matthew H. Porteus, Ravindra Majeti, Sanjay Malhotra, Mark Mercola
Summary: This study developed safer analogs of Ponatinib that retain potency against T315I BCR-ABL kinase activity and suppress T315I mutant CML tumor growth while significantly decreasing cardiotoxicity. The compounds showed improved safety in both in vitro and in vivo models.
Article
Oncology
John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, Chiao-En Wu
Summary: A novel nomogram was created in this study to help physicians suggest the optimal treatment for EGFRm+ NSCLC patients. The nomogram was based on pretreatment factors and stratified patients into five different risk groups for progression-free survival (PFS) and overall survival (OS). This risk stratification can provide additional information for clinicians and patients in determining the optimal therapeutic options.
Review
Oncology
Qi Zhu, Mingyun Jiang, Wenfei Li, Shuangli Sun, Jisheng Li, Justin Stebbing, Xiaodong Liang, Ling Peng
Summary: This study reported a case of a rare EGFR V786M mutation, which showed sensitivity to EGFR-TKIs and induced conformational changes. These findings provide evidence for further investigation.
FRONTIERS IN ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Martina Monti, Susanna Lunardini, Igino Andrea Magli, Riccardo Campi, Giulia Primiceri, Francesco Berardinelli, Daniele Amparore, Daniela Terracciano, Giuseppe Lucarelli, Luigi Schips, Matteo Ferro, Michele Marchioni
Summary: Renal cell carcinoma (RCC) is a common type of kidney cancer, and locally advanced or metastatic RCCs account for 15% of all diagnoses. Systemic therapies, primarily using tyrosine kinase inhibitors and immunotherapy, are the gold standard treatments. This study provides an overview of miRNAs as predictors of treatment resistance in RCC. Several miRNAs have shown association with resistance to systemic treatments or treatment failure. However, further validation and clinical use of these biomarkers are needed. Future large clinical trials are warranted to confirm the effectiveness of these tools in clinical decision-making.
Review
Oncology
Olivia Kronick, Xinyu Chen, Nidhi Mehra, Armon Varmeziar, Rachel Fisher, David Kartchner, Vamsi Kota, Cassie S. Mitchell
Summary: Tyrosine kinase inhibitors (TKIs) are the main class of drugs used to treat chronic myeloid leukemia. This study analyzed the prevalence of hematological adverse events (AEs) in patients treated with TKIs, and found significant differences in AE prevalence based on different TKI drug types and chronic myeloid leukemia phases.
Review
Clinical Neurology
Marian C. Brady, Myzoon Ali, Kathryn VandenBerg, Linda J. Williams, Louise R. Williams, Masahiro Abo, Frank Becker, Audrey Bowen, Caitlin Branden-burg, Caterina Breitenstein, Stefanie Bruehl, David A. Copland, Tamara B. Cranfill, Marie Di Pietro-Bachmann, Pamela Enderby, Joanne Fillingham, Federica Lucia Galli, Marialuisa Gandolfi, Bertrand Glize, Erin Godecke, Neil Hawkins, Katerina Hilari, Jacqueline Hinckley, Simon Horton, David Howard, Petra Jaecks, Elizabeth Jefferies, Luis M. T. Jesus, Maria Kambanaros, Eun Kyoung Kang, Eman M. Khedr, Anthony Pak-Hin Kong, Tarja Kukkonen, Marina Laganaro, Matthew A. Lambon Ralph, Ann Charlotte Laska, Beatrice Leemann, Alexander P. Leff, Roxele R. Lima, Antje Lorenz, Brian MacWhinney, Rebecca Shisler Marshall, Flavia Mattioli, ilknur MaviS, Marcus Meinzer, Reza Nilipour, Enrique Noe, Nam-Jong Paik, Rebecca Palmer, Ilias Papathanasiou, Brigida Patricio, Isabel Pavao Martins, Cathy Price, Tatjana Prizl Jakovac, Elizabeth Rochon, Miranda L. Rose, Charlotte Rosso, Ilona Rubi-Fessen, Marina B. Ruiter, Claerwen Snell, Benjamin Stahl, Jerzy P. Szaf-larski, Shirley A. Thomas, Mieke Van de Sandt-Koenderman, Ineke van der Meulen, Evy Visch-Brink, Linda Worrall, Heather Harris Wright
Summary: The aim of this study was to optimize speech and language therapy (SLT) regimens for maximal aphasia recovery. The analysis of data from 959 participants revealed that frequent, functionally tailored, receptive-expressive SLT, with prescribed home practice at a higher intensity and duration, were associated with the greatest language recovery.
Review
Health Care Sciences & Services
Valerie Aponte Ribero, Monica Daigl, Yasmina Marti, Ksenija Gorni, Rachel Evans, David Alexander Scott, Anadi Mahajan, Keith R. Abrams, Neil Hawkins
Summary: Indirect comparisons indicate that risdiplam is superior to nusinersen in terms of improved survival and motor function in Type 1 SMA. However, concrete conclusions couldn't be drawn due to substantial differences in study populations for comparisons with onasemnogene abeparvovec in Type 1 SMA and nusinersen in Types 2/3 SMA.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH
(2022)
Article
Cardiac & Cardiovascular Systems
Rita Faria, Pedro Saramago, Edward Cox, Stephen Weng, Barbara Iyen, Ralph K. Akyea, Steve E. Humphries, Nadeem Qureshi, Beth Woods
Summary: This study aimed to determine the long-term benefits and costs of diagnosing and treating FH based on prognostic factors and 'cholesterol burden'. A cost-effectiveness model was developed from the perspective of the UK NHS using routine data from FH patients. The results showed that diagnosing and treating FH resulted in positive net health gains, particularly in individuals with higher pre-treatment LDL-C.
Article
Medicine, General & Internal
Hannah Baker, Brooke Avey, Line Overbeck Rethmeier, Stuart Mealing, Marie Lynge Buchter, Marcio Augusto Averbeck, Nikesh Thiruchelvam
Summary: This study evaluated the cost-effectiveness of hydrophilic-coated intermittent catheters (HCICs) compared to uncoated intermittent catheters (UICs) from the perspective of the UK National Health Service. The results showed that HCICs are a cost-effective alternative to UICs, as they significantly reduce the occurrence of catheter-associated urinary tract infections.
CURRENT MEDICAL RESEARCH AND OPINION
(2023)
Review
Rheumatology
Bruno Fautrel, Jacoby Patterson, Catherine Bowe, Mick Arber, Julie Glanville, Stuart Mealing, Viviam Canon-Garcia, Laura Fagerhed, Hilde Rabijns, Roberto Giacomelli
Summary: This systematic review evaluated the efficacy and safety of biologic disease modifying anti-rheumatic drugs (bDMARDs) for adult-onset Still's disease (AOSD). The review included three randomized controlled trials, one retrospective case series, and 17 case series. Limited data from randomized controlled trials showed that bDMARDs may be effective compared to conventional DMARDs or placebo. However, the lack of standardized assessment criteria hindered comparisons between studies. Uncontrolled retrospective case series suggested that bDMARDs were effective in AOSD, but no comparative data were available. Standardization of therapeutic response definition and larger comparative studies are needed to determine the most effective bDMARDs for AOSD.
SEMINARS IN ARTHRITIS AND RHEUMATISM
(2023)
Article
Health Care Sciences & Services
Heather Davies, Joel Russell, Angel Varghese, Hayden Holmes, Marta O. Soares, B. Woods, Ruth Puig-Peiro, Stephanie Evans, Rory Tierney, Stuart Mealing, Mark Sculpher, Julie V. Robotham
Summary: This study developed a conceptual modeling framework to estimate the current and potential future consequences of antibiotic resistance on surgical procedures in England. The framework considered the impact of increasing antibiotic resistance on surgical site infection rates and the effectiveness of antibiotic treatment. The results showed the potential significant impact of antibiotic resistance on surgical outcomes and costs.
MDM POLICY & PRACTICE
(2023)
Article
Cardiac & Cardiovascular Systems
Maria Hee Jung Park Frausing, Jens Brock Johansen, Daniela Afonso, Ole Dan Jorgensen, Thomas Olsen, Christian Gerdes, Mette Lundsby Johansen, Claudia Wolff, Stuart Mealing, Jens Cosedis Nielsen, Mads Brix Kronborg
Summary: The use of an absorbable antibacterial envelope during implantation can effectively prevent cardiac implantable electronic device infections in patients with a moderate-to-high infection risk. A recent Danish study demonstrated that using an antibacterial envelope is cost-effective in patients undergoing cardiac resynchronization therapy (CRT) reoperations, in line with previous research conducted in other healthcare systems.
Article
Economics
Sam Harper, Lukasz Grodzicki, Stuart Mealing, Liz Gemmill, Paul J. Goldsmith, Ahmed R. Ahmed
Summary: This study assessed the cost-effectiveness of RefluxStop compared with other treatment options for GERD. The results showed that RefluxStop had better surgical outcomes and was highly likely to be a cost-effective treatment option within the UK National Health Service.
JOURNAL OF MEDICAL ECONOMICS
(2023)
Article
Economics
A. Looby, H. Davies, S. Mealing, A. B. Smith, B. Avey, A. Laezza, A. Crossland, E. F. Lane, M. Ridler, M. Cawson
Summary: This study aimed to assess the utility decrements associated with three attributes of catheterization for individuals with spinal cord injuries. Health state vignettes and an online time trade-off questionnaire were used to collect data, and the results showed that community residence and the process of catheterization had significant impacts on health utility.
JOURNAL OF MEDICAL ECONOMICS
(2023)
Article
Health Care Sciences & Services
Nadeem Qureshi, Bethan Woods, Rita Neves de Faria, Pedro Saramago Goncalves, Edward Cox, Jo Leonardi Bee, Laura Condon, Stephen Weng, Ralph K. Akyea, Barbara Iyen, Paul Roderick, Steve E. Humphries, William Rowlands, Melanie Watson, Kate Haralambos, Ryan Kenny, Dev Datta, Zosia Miedzybrodzka, Christopher Byrne, Joe Kai
Summary: Cascade testing of relatives of people with familial hypercholesterolaemia is an effective approach, but different testing protocols have varying yields, treatment patterns, and outcomes. Cost-effectiveness analysis suggests that starting with genetically confirmed index cases and directly contacting first- and second-degree relatives has the most health gain. Interviews indicate that a service-led direct-contact approach is more reliable, but combining direct and indirect approaches may be more acceptable.
HEALTH TECHNOLOGY ASSESSMENT
(2023)
Article
Medicine, General & Internal
Maria Hollmen, Marlies Wijsenbeek, Tom Bromilow, Adam B. Smith, Stuart Mealing, Damian Lewis, Liam Galvin, Steve Jones, Guus Asijee, Stephane Soulard, Antoine Froidure
Summary: This study aimed to investigate the preferences of IPF patients, caregivers, and pulmonologists regarding the treatment profiles of AF drugs using a DCE. The findings showed that patients and caregivers prioritized the management of treatment-related adverse events, while pulmonologists emphasized lung function and exacerbations control. These differences should be taken into account by clinicians to involve patients in IPF treatment decision-making.
PATIENT PREFERENCE AND ADHERENCE
(2023)
Article
Health Care Sciences & Services
Neil Hawkins, Noemi Muszbek, Rachel Evans, Linda Mcnamara, Trefor Jones
Summary: This study analyzed real-world data of patients with advanced mycosis fungoides/Sezary syndrome (MF/SS) and found significant improvement in overall survival (OS) with mogamulizumab treatment compared to UK clinical practice, indicating a potential advantage of using mogamulizumab in this patient population.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH
(2023)
Article
Economics
Maria Mata Lorenzo, Mahmood Ali, Stuart Mealing, Joe Moss
Summary: Through a health economic model, this study evaluates the cost-effectiveness of roxadustat compared to ESAs for treating anemia of non-dialysis-dependent CKD. The model incorporates a hypothetical cohort of 1,000 NDD CKD patients and considers eight different health states representing varying levels of anemia. Results show that roxadustat is on average less costly and more effective than ESAs, with a dominant incremental cost-effectiveness ratio. The model highlights the potential cost-effectiveness and impact of roxadustat in reducing the burden of anemia in NDD CKD patients.
JOURNAL OF MEDICAL ECONOMICS
(2023)
Article
Cardiac & Cardiovascular Systems
Oussama Wazni, Joe Moss, Malte Kuniss, Jason Andrade, Gian Battista Chierchia, Stuart Mealing, Waruiru Mburu, Alicia Sale, Rachelle Kaplon, Eleni Ismyrloglou, Tom Bromilow, Emily Lane, Damian Lewis, Matthew R. Reynolds
Summary: From the perspective of U.S. Medicare payers, initial rhythm control with first-line cryoballoon ablation is highly cost-effective compared with first-line antiarrhythmic drugs (AADs).
Review
Health Care Sciences & Services
Nadeem Qureshi, Bethan Woods, Rita Neves de Faria, Pedro Saramago Goncalves, Edward Cox, Jo Leonardi-Bee, Laura Condon, Stephen Weng, Ralph K. Akyea, Barbara Iyen, Paul Roderick, Steve E. Humphries, William Rowlands, Melanie Watson, Kate Haralambos, Ryan Kenny, Dev Datta, Zosia Miedzybrodzka, Christopher Byrne, Joe Kai
Summary: The study found that the combined approach yielded more relatives tested compared to the direct and indirect approaches in cascade testing. Hospital data indicated that those directly contacted were more likely to complete cascade testing. The cost-effectiveness analysis found that contacting first and second-degree relatives directly was the most cost-effective approach. The study also found that combining direct and indirect approaches may be more acceptable to families and healthcare providers.
HEALTH TECHNOLOGY ASSESSMENT
(2023)
